Published in Arch Dermatol on April 01, 1977
Treatment of facial Basal cell carcinoma: a review. J Skin Cancer (2011) 1.41
Focus on Basal cell carcinoma. J Skin Cancer (2010) 0.96
Modeling capsule tissue growth around disk-shaped implants: a numerical and in vivo study. J Math Biol (2008) 0.85
Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery. Dermatol Surg (2008) 0.83
Radiotherapy of periocular basal cell carcinomas: recurrence rates and treatment with special attention to the medical canthus. Br J Ophthalmol (1988) 0.83
Modern Chemosurgery--microscopically controlled excision. West J Med (1980) 0.75
A reliable frozen section technique for basal cell carcinomas of the head and neck. Plast Surg (Oakv) (2014) 0.75
Procedures in dermatology. Br Med J (Clin Res Ed) (1988) 0.75
The Viviparous-1 developmental gene of maize encodes a novel transcriptional activator. Cell (1991) 6.84
Analysis of partial volume effects in diffusion-tensor MRI. Magn Reson Med (2001) 3.66
Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin (1985) 2.57
Ultraviolet A and melanoma: a review. J Am Acad Dermatol (2001) 2.27
Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol (1990) 2.10
Malignant melanoma. A controlled study of possibly associated factors. Arch Dermatol (1969) 2.06
Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol (1992) 1.94
Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91
Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol (2000) 1.88
Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol (1991) 1.80
Precision of automatic measurements of pigmented skin lesion parameters with a MelaFind(TM) multispectral digital dermoscope. Melanoma Res (2000) 1.78
Hypomelanosis of Ito ("incontinentia pigmenti achromians"). Report of three cases and review of the literature. Arch Dermatol (1973) 1.77
C-terminal domains of human translation termination factors eRF1 and eRF3 mediate their in vivo interaction. FEBS Lett (1999) 1.77
Solar nevogenesis: a surrogate for predicting a rise in incidence of malignant melanoma because of ozone depletion. J Am Acad Dermatol (1993) 1.73
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Obtaining consent for eye donation. Isr J Med Sci (1991) 1.64
Bowenoid papulosis of the genitalia. Arch Dermatol (1979) 1.62
Risk of melanoma in medium-sized congenital melanocytic nevi: a follow-up study. J Am Acad Dermatol (1998) 1.60
Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis. Pediatrics (2000) 1.56
Cutaneous horns. A clinical and histopathologic study. Acta Derm Venereol (1968) 1.55
Non-melanoma skin cancer among Caucasians in four areas of the United States. Cancer (1974) 1.55
Brittle cornea. A familial trait associated with blue sclera. Am J Ophthalmol (1968) 1.53
Malignant melanoma: a review. J Dermatol Surg Oncol (1977) 1.52
The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol (1996) 1.48
Reproducibility of topographic measures of the glaucomatous optic nerve head. Br J Ophthalmol (1998) 1.46
The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med (1981) 1.45
Congenital nevocytic nevi and malignant melanomas. J Am Acad Dermatol (1979) 1.45
Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer (2000) 1.44
Tono-Pen tonometry in normal and in post-keratoplasty eyes. Br J Ophthalmol (1992) 1.42
Giant cavernous hemangioma of the face. Arch Ophthalmol (1994) 1.39
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38
Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38
Isolation of murine neuron-specific and non-neuronal enolase cDNA clones. Biochem Biophys Res Commun (1986) 1.36
Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg (1981) 1.34
A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery (1981) 1.33
Congenital fibrosis of the extraocular muscles (autosomal dominant congenital external ophthalmoplegia): genetic homogeneity, linkage refinement, and physical mapping on chromosome 12. Am J Hum Genet (1995) 1.30
Knuckle pads, leukonychia and deafness. A dominantly inherited syndrome. N Engl J Med (1967) 1.30
Chloramphenicol optic neuropathy. Arch Ophthalmol (1980) 1.29
Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. J Am Acad Dermatol (1996) 1.27
A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg (1982) 1.24
Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry. Br J Dermatol (2005) 1.23
Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol (1996) 1.20
Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer (1995) 1.18
On a dilemma of penile horns: pseudoepitheliomatous, hyperkeratotic and micaceous balanitis? J Dermatol Surg Oncol (1978) 1.16
The recurrent basal cell epithelioma. A study of 100 cases of recurrent, re-treated basal cell epitheliomas. Arch Dermatol (1971) 1.15
[Studies of the method of culture of N. gonorrhoeae in tissue cultures]. Actas Dermosifiliogr (1970) 1.15
A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. J Am Acad Dermatol (1997) 1.15
Collapse of the N=28 shell closure in (42)Si. Phys Rev Lett (2007) 1.13
Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol (1995) 1.13
[Pathogenesis and therapy of tetanus]. Schweiz Med Wochenschr (1970) 1.13
Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol (1984) 1.12
Recurrence rates of treated basal cell carcinomas. Part 1: Overview. J Dermatol Surg Oncol (1991) 1.12
Age and malignant melanoma: comparison of variables in different age-groups. J Am Acad Dermatol (1989) 1.11
Diagnostic accuracy in malignant melanoma. Arch Dermatol (1975) 1.09
"The disappearing lens": failure of CT to image the lens in traumatic intumescent cataract. J Comput Assist Tomogr (1999) 1.08
Scalpel excision of basal cell carcinomas. Arch Dermatol (1978) 1.08
Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin (2001) 1.07
Diacetyl nadolol: 3-month ocular hypotensive effect in glaucomatous eyes. Br J Ophthalmol (1983) 1.06
Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin. CA Cancer J Clin (1991) 1.06
Three-point checklist of dermoscopy: an open internet study. Br J Dermatol (2006) 1.04
Prognostic index for malignant melanoma. Cancer (1987) 1.04
Effect of anatomical location on prognosis in patients with clinical stage I melanoma. Arch Dermatol (1983) 1.04
Serotypes of Ureaplasma urealyticum isolated from patients with nongonococcal urethritis and gonorrhea and from asymptomatic urethral carriers. Sex Transm Dis (1986) 1.03
The rate of malignant melanoma in the United States: are we making an impact? J Am Acad Dermatol (1987) 1.02
Sun and malignant melanoma. J Am Acad Dermatol (1984) 1.02
Risk factors for the development of malignant melanoma--I: Review of case-control studies. J Dermatol Surg Oncol (1988) 1.02
Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol (1993) 1.02
Syndromes associated with melanocytic nevi. J Am Acad Dermatol (1993) 1.01
Acquired digital fibrokeratomas. Arch Dermatol (1968) 1.01
Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol (1992) 1.01
Cutaneous malignant melanoma: prognostic guidelines for physicians and patients. CA Cancer J Clin (1982) 1.01